Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Links shared publicly online about this topic.

725
total visits

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD i

View full resource at news-medical.net

Tags: ADHD, ADHD Medication, Disease and Condition, Drug, FDA, Vyvanse, Shire